NewAmsterdam Pharma Company N.V. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
NewAmsterdam Pharma Company N.V. (NAMS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $7.78 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $5.60, a 70.21% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.29, a 159.06% increase year-over-year.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $1.27.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $8.18, a 108.14% increase from fiscal 2024.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.93, a 117.13% increase from fiscal 2023.
- NewAmsterdam Pharma Company N.V. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.81.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.78 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $5.60 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $8.18 10-K · filed 2026-02-18 | |||
| 2025-09-30 | $6.43 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $5.21 10-Q · filed 2025-08-06 | |||
| 2025-03-31 | $3.29 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $3.93 10-K · filed 2025-02-26 | |||
| 2024-09-30 | $1.27 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $1.27 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $1.27 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $1.81 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |